Chang SC 2015[ |
China | 182 | S:44/32 | S:55.89 | ---- | metastatic or recurrent GISTs | imatinib | Preop + Postop |
R0 30 R1 9 R2 37 |
---- | Retrospective |
NS:66/40 | NS:58.42 | ||||||||||
Zaydfudim V 2015[ |
USA | 87 | S:31/23 | S:61 |
S:9 NS:9 |
metastatic or recurrent GISTs | Imatinib or sunitinib | Preop + Postop |
R0 32 R1 3 R2 19 |
---- | Retrospective |
NS:17/16 | NS:60 | ||||||||||
Sato S 2016 [ |
Japan | 93 | S:28/22 | S:60 | S:7.5 | metastatic or recurrent GISTs | Imatinib | Postop only |
R0 29 R1 5 R2 13 |
75.2 | Retrospective |
NS:28/15 | NS:69.7 | NS:8 | |||||||||
Shi YN 2017 [ |
China | 130 | 90/54 | 56 | ---- | metastatic GISTs | Imatinib then sunitinib | Postop only |
R0 23 R1/R2 9 |
48.2 | Retrospective |
Xiao B 2018 [ |
China | 102 | S:11/10 | 52 | 4.4 | metastatic GISTs | Imatinib then sunitinib | Postop only |
R0 15 R1/R2 6 |
---- | Retrospective |
NS:60/21 | |||||||||||
Xia L 2010 [ |
China | 39 | S:10/9 | 53 | S: 8.9 | metastatic GISTs | Imatinib | Preop + Postop | ---- | 36 | Retrospective |
NS:11/9 | 55 | N:9.3 | |||||||||
Bauer S 2005[ |
USA | 90 | S:6/6 | S:57 | ----- | Metastatic GISTs | Imatinib | Preop + Postop |
R0 11 R1/R2 1 |
---- | Retrospective |
NS:45/33 | NS:62 | ||||||||||
Xue A 2022 [ |
China | 119 | S:34/28 | 56 | 4 | metastatic GISTs | imatinib | Preop + Postop |
R0 44 R1 16 R2 2 |
56 | Retrospective |
NS:37/20 |
Chang SC 2015[ |
4 | 1 | 3 | 8 |
Zaydfudim V 2015[ |
4 | 1 | 2 | 7 |
Sato S 2016 [ |
4 | 1 | 2 | 7 |
Shi YN 2017 [ |
4 | 1 | 2 | 7 |
Xiao B 2018 [ |
4 | 1 | 3 | 8 |
Xia L 2010 [ |
4 | 1 | 2 | 7 |
Bauer S 2005[ |
4 | 1 | 3 | 8 |
Xue A 2022 [ |
4 | 1 | 3 | 8 |